Chief Executive Officer and Director
Ken d’Entremont is the founder, president, and CEO of Medexus Inc. Previously, he was the general manager and vice president of business development at Sanofi, where he led the in-licensing initiatives for Sanofi Canada. Mr. d’Entremont holds a Bachelor of Science in Chemistry from McMaster University.
Chief Financial Officer
Mr. Konrad joins the Company from CareDx, Inc. (Nasdaq: CDNA), a precision medicine solutions company, where he has served as Senior Vice President Finance & Accounting and Vice President, Corporate Controller since 2018, including a stint as acting Chief Financial Officer in early 2021. While at CareDx, Inc., Mr. Konrad was tasked with scaling multinational accounting, finance and business operations including streamlining processes and systems while navigating the integration of various financings and cross-border acquisitions.
Prior to joining CareDx, Inc., Mr. Konrad worked in similar roles at Santen Inc., a US subsidiary of a publicly listed Japanese pharmaceutical company with global operations, and held various roles at Novartis Pharmaceuticals, both in the US and Switzerland. Mr. Konrad holds an International MBA from the University of San Diego and graduated Business Administration from HEC Lausanne, University of Lausanne, Switzerland. Mr. Konrad is an active US Certified Public Accountant and during his tenure at Novartis has completed the Finance Leadership Program at the Harvard Business School.
General Manager, U.S. Operations
Michael Adelman joined Medexus in 2020 from Aptevo Therapeutics, where he led all commercial functions as SVP, Commercial Operations. Mr. Adelman has over 25 years of life-science commercial experience, including leadership roles at Emergent BioSolutions, Cangene, Adolor, and AstraZeneca. Mr. Adelman holds a Bachelor of Science in Finance from Northeastern University and Master of Business Administration from New York University’s Stern School of Business.
Senior Vice President of Business Development and Strategy
Michael Pine joined Medexus in 2020 from Lupin Pharmaceuticals, where he served as SVP BD&L, responsible for expanding further into branded specialty products. Mr. Pine has over 20 years of experience as a pharmaceutical industry executive and business leader with a diverse background in both large and small pharmaceutical companies that includes functions in: business development & licensing, M&A, investment banking, strategy, marketing, US managed markets, and operations. Prior positions include senior roles at companies such as Aralez, Novartis, Kos Pharmaceuticals, Organon, Pfizer, and JP Morgan Chase. Mr. Pine has a BS in Consumer Economics from Cornell University and an MBA from Columbia Business School.
Vice President Allergy, Pediatric and OTC Portfolios, Canadian Operations
Richard Labelle joined Medexus (Pediapharm legacy) in February of 2014. Previously he was the general manager and vice president of the consumer portfolio at Sanofi. He has held several management positions including heading commercial operations for the cardiovascular and osteoporosis divisions. He also led the business development team at Aventis. Mr. Labelle holds a Bachelor of Commerce from University of Quebec and a Master of Business Administration from McGill – HEC executive program.
Vice President Specialty Markets, Canadian Operations
Kerry Bakewell joined Medexus in January of 2002, as Director of Sales and Marketing. She has over 30 years of experience in the pharmaceutical industry, including several management positions at Merck Frosst and Sanofi. She has played an integral role in the growth and success of the Specialty Markets Division in Canada. Miss Bakewell holds a Bachelor of Science degree from The University of Alberta.